Interplay between Hepatitis C Virus and Redox Cell Signaling

Hepatitis C virus (HCV) infects approximately 3% of the world’s population. Currently licensed treatment of HCV chronic infection with pegylated-interferon-α and ribavirin, is not fully effective against all HCV genotypes and is associated to severe side effects. Thus, development of novel therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggieri, Anna, Anticoli, Simona, Nencioni, Lucia, Sgarbanti, Rossella, Garaci, Enrico, Palamara, Anna Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634496/
https://www.ncbi.nlm.nih.gov/pubmed/23443167
http://dx.doi.org/10.3390/ijms14034705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634496/
https://www.ncbi.nlm.nih.gov/pubmed/23443167
http://dx.doi.org/10.3390/ijms14034705

Ejemplares similares